Real-World Practice Patterns for Prevention and Management of Potential Adverse Events with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Abstract Introduction Pirfenidone is an oral antifibrotic agent approved for idiopathic pulmonary fibrosis (IPF). Real-world data on adverse event (AE) management for pirfenidone are limited. Strategies for managing potential antifibrotic therapy AEs were examined in a sample of US pulmonologists. M...
Main Authors: | Mark L. Wencel, Tmirah Haselkorn, Susan L. Limb, John L. Stauffer, Elizabeth Morgenthien, Karina Raimundo, Peter P. LaCamera |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2018-06-01
|
Series: | Pulmonary Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1007/s41030-018-0056-8 |
Similar Items
-
Efficacy and safety of combination therapy with pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis
by: Jin-Young Huh, et al.
Published: (2023-12-01) -
Genetic variations in idiopathic pulmonary fibrosis and patient response to pirfenidone
by: Aahd Kubbara, et al.
Published: (2023-08-01) -
Antifibrotic therapy of idiopathic pulmonary fibrosis: efficiency / safety ratio
by: S. N. Avdeev, et al.
Published: (2018-10-01) -
Idiopathic pulmonary fibrosis: a clinical case of long-term follow-up
by: Galina L. Ignatova, et al.
Published: (2022-09-01) -
Effects of Pirfenidone on Idiopathic Pulmonary Fibrosis Progression and Safety: Results of Multicenter Prospective Observational Study
by: Sergey Avdeev, et al.
Published: (2023-02-01)